Irina Nickeleit

TL;DR: This work identifies argyrin A, a cyclical peptide derived from the myxobacterium Archangium gephyra, as a potent antitumoral drug and finds that the biological effects of proteasome inhibition per se depend on the expression of p27(kip1).

TL;DR: The results unveil the molecular composition of a pathway, which regulates the abundance and activity of p27kip1 during early G1 and explain how the T187‐ and the T198‐dependent turnover systems synergize to allow cell cycle progression in G1.

TL;DR: It is shown that human and mouse CCCs are characterized by high expression of the Cyclin E protein and identified the cyclin E gene as a direct transcriptional target of the Notch signaling pathway and blocking γ-secretase activity in human CCC xenotransplants results in downregulation of cyclinE expression, induction of apoptosis, and tumor remission in vivo.

TL;DR: In the quest for new targets for antitumor therapy, the proteasome and its inhibitors have been the focus of academic and industrial research and data already support the high potential of argyrin A as a potential drug candidate, but detailed structure–activity relationship studies, and a molecular understanding of its mode-of-action are a prerequisite for the further optimization of its medicinal potential.